Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Share:

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2021, Vol. 26 ›› Issue (3): 299-304.doi: 10.12092/j.issn.1009-2501.2021.03.009

Previous Articles     Next Articles

Bioequivalence of solifenacin succinate tablets in healthy Chinese volunteers

WANG Hui1,2, CUI Chang1,2, YANG Shuang1,2, YAO An1,2, WU Shuting1,2, YANG Xiaoyan1,2, YE Ling1,2, ZOU Zhi3, TANG Zhi3, YANG Guoping1,2, HUANG Jie1,2, OUYANG Dongsheng3   

  1. 1 Center of Clinical Pharmacology, the Third Xiangya Hospital, Central South University, Changsha 410013, Hunan, China; 2 Research Center of Drug Clinical Evaluation of Central South University, Changsha 410013, Hunan, China; 3 Changsha Duxact Biotech Co, Ltd., Changsha 410000, Hunan, China
  • Received:2020-12-07 Revised:2021-02-05 Online:2021-03-26 Published:2021-04-06

Abstract: AIM: To evaluate the bioequivalence of the test and reference preparations of solifenacin succinate tablets administered once orally under fasting and fed conditions in Chinese healthy volunteers.  METHODS: The study was designed as single-center, randomized, open, self-crossover and twenty four healthy volunteers were recruited respectively in fasting and fed conditions. Subjects were assigned to receive a single oral of the test or reference formulation per period at a dose of 10 mg. The plasma concentration of solifenacin was analyzed by LC-MS/MS. The major pharmacokinetic parameters were calculated by WinNonlin 7.0, then the bioequivalence was evaluated.RESULTS: The main pharmacokinetic parameters of a single oral solifenacin succinate under fasting condition for test and reference preparation were as follows: Cmax (13.99±3.34) and (13.27±3.20) ng/mL, AUC0-t (675.60±210.46) and (653.31±238.59) h·ng·mL-1, AUC0-∞(728.28±240.20) and (718.14±275.63) h·ng·mL-1, tmax (5.00±1.41) h and (4.98±1.07) h, t1/2 (39.19±9.29) and (42.44±12.66) h. The relative bioavailability was 105.06% for AUC0-t, 104.07% for AUC0-∞. The main pharmacokinetic parameters of a single oral solifenacin succinate under fed condition for test and reference preparation were as follows: Cmax (15.65±5.30), (15.02±4.42) ng/mL; AUC0-t (808.85±271.19), (793.76±256.78) h·ng·mL-1; AUC0-∞ (917.02±347.82), (875.49±310.77) h·ng·mL-1. tmax (4.29±1.48) h and (5.69±4.10) h, t1/2 (49.47±20.08) and (45.29±12.24) h. The relative bioavailability was 100.91% for AUC0-t, 102.97% for AUC0-∞. The 90% confidence intervals of the geometric mean ratios of the main pharmacokinetic parameters Cmax, AUC0-t, AUC0-∞ of the two preparations under fasting/feding conditions were all within 80%-125%.CONCLUSION: The test and reference preparation of solifenacin succinate tablets are bioequivalent under fasting and fed conditions.

Key words: solifenacin succinate, LC-MS/MS, bioequivalence, pharmacokinetic

CLC Number: